Stay updated with breaking news from Cambridge asset. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation. Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform March 12, 2021 GMT BOSTON (BUSINESS WIRE) Mar 12, 2021 Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer. ....
RTW Participates in $95 Million Financing Round in Monte Rosa Therapeutics RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Monte Rosa Therapeutics, Inc. ( Monte Rosa ) on 12 March 2021 of its completion of a $95 million Series C financing round. The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms. Monte Rosa is a privately held preclinical-stage biotech company discovering and developing small molecule degraders (also known as molecular glues) to eliminate disease-causing proteins. Monte Rosa plans to use the proceeds from the financing round to advance its lead development candidate into the clinic, accelerate pipeline growth and ....